Latest News Mark Humayun, MD, PhD, Named Keynote Speaker for Envision Conference By Staff Monday, January 23, 2017 12:18 AM Mark S. Humayun, MD, PhD. WICHITA, Kan.—Envision announced that Mark S. Humayun, MD, PhD, will deliver the keynote address at the 12th annual Envision Conference. The conference will take place July 26 to 29 at the Renaissance Phoenix Glendale Hotel & Spa in Ariz., providing opportunities for low vision professionals in multidisciplinary fields to exchange ideas and information, according to Envision.“We are honored to have Mark Humayun as our keynote speaker,” said Michael Epp, manager of professional education at Envision. “Dr. Humayan’s groundbreaking work in biotechnology coupled with his commitment to education and his many awards, certifications and professional association memberships keep him active on the front lines of vision research and care. We expect his address to be the catalyst to many fervent and fruitful discussions over the course of our four-day conference.”The recipient of the 2015 National Medal of Technology and Innovation from President Obama, Dr. Humayun has more than 100 patents and patent applications to his name and co-invented the Argus Series retina implant—a “bionic eye” manufactured by Second Sight—that is intended to induce visual perception. His presentation at Envision Conference 2017 will discuss the genesis of the Argus II and address the importance of innovation in addressing vision loss.Dr. Humayun is also co-director of the University of Southern California (USC) Roski Eye Institute, director of the USC Institute for Biomedical Therapeutics, the Cornelius J. Pings Chair in Biomedical Sciences at the Keck School of Medicine of USC and a professor of ophthalmology, biomedical engineering, cell and neurobiology and director of sensory science initiatives at USC.Registration for the conference is now open and submissions are currently being accepted for prospective clinical education and research abstract presentations. Visit envisionconference.org for more details.